Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung

Tomoya Fukui, Koji Tsuta, Koh Furuta, Shun ichi Watanabe, Hisao Asamura, Yuichiro Ohe, Akiko Miyagi Maeshima, Tatsuhiro Shibata, Noriyuki Masuda, Yoshihiro Matsuno

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

In lung cancer, somatic mutations of epidermal growth factor receptor (EGFR) are concentrated in exons 18-21, especially in adenocarcinoma (Ad), but these mutations have rarely been reported in small cell lung carcinoma (SCLC). Combined SCLC is rare, and the EGFR mutation status and its relationship to the clinicopathological features of this tumor type have not yet been elucidated. We retrospectively studied six patients with combined SCLC with Ad components among 64 consecutive patients who underwent resection of SCLC. The clinicopathological features of each patient were reviewed, especially for the distribution pattern of the Ad component and lymph node metastases. EGFR mutations were screened by high-resolution melting analysis in each case, and were confirmed by sequencing of each mutation in the microdissected SCLC or Ad components. Regarding EGFR, no specific mutation was detected in five of the six patients, whereas one female patient who had never smoked had a missense mutation. In this case, both the SCLC and Ad components shared the same mutation in exon 21 (L858R). We identified a patient with combined SCLC with Ad sharing an identical EGFR mutation in both the SCLC and Ad components. In addition to the clinicopathological characteristics of this rare histological type of lung cancer, these findings provide useful information for better understanding the biology, natural history and clinical management of SCLC.

Original languageEnglish
Pages (from-to)1714-1719
Number of pages6
JournalCancer Science
Volume98
Issue number11
DOIs
Publication statusPublished - 2007 Nov
Externally publishedYes

Fingerprint

Small Cell Carcinoma
Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Mutation
Adenocarcinoma
Exons
Lung Neoplasms
Adenocarcinoma of lung
Missense Mutation
Natural History
Freezing
Lymph Nodes
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. / Fukui, Tomoya; Tsuta, Koji; Furuta, Koh; Watanabe, Shun ichi; Asamura, Hisao; Ohe, Yuichiro; Maeshima, Akiko Miyagi; Shibata, Tatsuhiro; Masuda, Noriyuki; Matsuno, Yoshihiro.

In: Cancer Science, Vol. 98, No. 11, 11.2007, p. 1714-1719.

Research output: Contribution to journalArticle

Fukui, Tomoya ; Tsuta, Koji ; Furuta, Koh ; Watanabe, Shun ichi ; Asamura, Hisao ; Ohe, Yuichiro ; Maeshima, Akiko Miyagi ; Shibata, Tatsuhiro ; Masuda, Noriyuki ; Matsuno, Yoshihiro. / Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. In: Cancer Science. 2007 ; Vol. 98, No. 11. pp. 1714-1719.
@article{96ae31f64768400da7906c398346a04a,
title = "Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung",
abstract = "In lung cancer, somatic mutations of epidermal growth factor receptor (EGFR) are concentrated in exons 18-21, especially in adenocarcinoma (Ad), but these mutations have rarely been reported in small cell lung carcinoma (SCLC). Combined SCLC is rare, and the EGFR mutation status and its relationship to the clinicopathological features of this tumor type have not yet been elucidated. We retrospectively studied six patients with combined SCLC with Ad components among 64 consecutive patients who underwent resection of SCLC. The clinicopathological features of each patient were reviewed, especially for the distribution pattern of the Ad component and lymph node metastases. EGFR mutations were screened by high-resolution melting analysis in each case, and were confirmed by sequencing of each mutation in the microdissected SCLC or Ad components. Regarding EGFR, no specific mutation was detected in five of the six patients, whereas one female patient who had never smoked had a missense mutation. In this case, both the SCLC and Ad components shared the same mutation in exon 21 (L858R). We identified a patient with combined SCLC with Ad sharing an identical EGFR mutation in both the SCLC and Ad components. In addition to the clinicopathological characteristics of this rare histological type of lung cancer, these findings provide useful information for better understanding the biology, natural history and clinical management of SCLC.",
author = "Tomoya Fukui and Koji Tsuta and Koh Furuta and Watanabe, {Shun ichi} and Hisao Asamura and Yuichiro Ohe and Maeshima, {Akiko Miyagi} and Tatsuhiro Shibata and Noriyuki Masuda and Yoshihiro Matsuno",
year = "2007",
month = "11",
doi = "10.1111/j.1349-7006.2007.00600.x",
language = "English",
volume = "98",
pages = "1714--1719",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung

AU - Fukui, Tomoya

AU - Tsuta, Koji

AU - Furuta, Koh

AU - Watanabe, Shun ichi

AU - Asamura, Hisao

AU - Ohe, Yuichiro

AU - Maeshima, Akiko Miyagi

AU - Shibata, Tatsuhiro

AU - Masuda, Noriyuki

AU - Matsuno, Yoshihiro

PY - 2007/11

Y1 - 2007/11

N2 - In lung cancer, somatic mutations of epidermal growth factor receptor (EGFR) are concentrated in exons 18-21, especially in adenocarcinoma (Ad), but these mutations have rarely been reported in small cell lung carcinoma (SCLC). Combined SCLC is rare, and the EGFR mutation status and its relationship to the clinicopathological features of this tumor type have not yet been elucidated. We retrospectively studied six patients with combined SCLC with Ad components among 64 consecutive patients who underwent resection of SCLC. The clinicopathological features of each patient were reviewed, especially for the distribution pattern of the Ad component and lymph node metastases. EGFR mutations were screened by high-resolution melting analysis in each case, and were confirmed by sequencing of each mutation in the microdissected SCLC or Ad components. Regarding EGFR, no specific mutation was detected in five of the six patients, whereas one female patient who had never smoked had a missense mutation. In this case, both the SCLC and Ad components shared the same mutation in exon 21 (L858R). We identified a patient with combined SCLC with Ad sharing an identical EGFR mutation in both the SCLC and Ad components. In addition to the clinicopathological characteristics of this rare histological type of lung cancer, these findings provide useful information for better understanding the biology, natural history and clinical management of SCLC.

AB - In lung cancer, somatic mutations of epidermal growth factor receptor (EGFR) are concentrated in exons 18-21, especially in adenocarcinoma (Ad), but these mutations have rarely been reported in small cell lung carcinoma (SCLC). Combined SCLC is rare, and the EGFR mutation status and its relationship to the clinicopathological features of this tumor type have not yet been elucidated. We retrospectively studied six patients with combined SCLC with Ad components among 64 consecutive patients who underwent resection of SCLC. The clinicopathological features of each patient were reviewed, especially for the distribution pattern of the Ad component and lymph node metastases. EGFR mutations were screened by high-resolution melting analysis in each case, and were confirmed by sequencing of each mutation in the microdissected SCLC or Ad components. Regarding EGFR, no specific mutation was detected in five of the six patients, whereas one female patient who had never smoked had a missense mutation. In this case, both the SCLC and Ad components shared the same mutation in exon 21 (L858R). We identified a patient with combined SCLC with Ad sharing an identical EGFR mutation in both the SCLC and Ad components. In addition to the clinicopathological characteristics of this rare histological type of lung cancer, these findings provide useful information for better understanding the biology, natural history and clinical management of SCLC.

UR - http://www.scopus.com/inward/record.url?scp=34748863599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748863599&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2007.00600.x

DO - 10.1111/j.1349-7006.2007.00600.x

M3 - Article

VL - 98

SP - 1714

EP - 1719

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 11

ER -